An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Kennedy called for easier access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how policymakers view compounded peptide therapies, which have drawn increasing interest from consumers seeking alternatives to conventional drugs. Scientists say peptide treatments could reshape approaches to resistant infections, though concerns about safety persist. The committee's endorsement of four peptides paves the way for more expanded prescribing, even as watchdogs warn of short-term evidence. Market watchers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on certain peptide candidates.